Scholarlink

<p>The most common kind of kidney cancer, clear cell renal cell carcinoma (ccRCC), presents challenges in clinical management and prognosis. Although the roles of long non-coding RNAs (lncRNAs) and migrasomes in tumorigenesis and tumor development have gradually attracted attention, there is currently relatively little research on migrasomes in ccRCC. The objective of this research was to construct a migrasome-associated lncRNAs model and assess its predictive value for immune reactions and survival outcomes in patients with ccRCC. First, the Cancer Genome Atlas (TCGA) database was utilized to acquire transcriptome data and clinical information pertaining to ccRCC. Using this data, Pearson correlation identified migrasome-associated lncRNAs, and Cox regression analysis was utilized to build a prognostic model. Subsequently, the model’s utility was validated against clinical characteristics from multiple perspectives. Enrichment results, immune infiltration analysis, Tumor Mutational Burden (TMB), and Tumor Immune Dysfunction and Exclusion (TIDE) analysis delineated differences in the tumor immune microenvironment. Quantitative real-time polymerase chain reaction (qPCR) confirmed the expression of key lncRNAs in the model. Finally, a interference plasmid for UBE2Q1-AS1 was constructed and transfected into 786-O cells. The CCK-8 assay and Transwell assay were then used to verify its effects on cell proliferation and migration. A prognostic model incorporating 12 migrasome-associated lncRNAs with independent prognostic value was developed, demonstrating robust predictive power across various clinical features. Enrichment and immune infiltration analyses revealed significant disparities in immune responses between groups. TMB and TIDE analyses indicated that high TMB groups had lower survival rates compared to low TMB groups, and TIDE scores were greater for high-risk groups than for low-risk groups. Additionally, the quantities of expression for migrasome-associated lncRNAs were validated in human ccRCC cell line. Cell experiments revealed that interference of UBE2Q1-AS1 significantly inhibited the proliferation and migration of 786-O cells. The migrasome-associated lncRNA model accurately predicts ccRCC patient prognosis, offering new insights for immunotherapy and clinical applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A novel migrasome-associated lncRNA model for clear cell renal cell carcinoma prognosis and immune response prediction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月11日

查看全文
  • Linlin Zhang,
  • Longxin Dong,
  • Tengzheng Tian,
  • Jing Liu,
  • Haozhe Zhang,
  • Weitao Zhang

摘要

The most common kind of kidney cancer, clear cell renal cell carcinoma (ccRCC), presents challenges in clinical management and prognosis. Although the roles of long non-coding RNAs (lncRNAs) and migrasomes in tumorigenesis and tumor development have gradually attracted attention, there is currently relatively little research on migrasomes in ccRCC. The objective of this research was to construct a migrasome-associated lncRNAs model and assess its predictive value for immune reactions and survival outcomes in patients with ccRCC. First, the Cancer Genome Atlas (TCGA) database was utilized to acquire transcriptome data and clinical information pertaining to ccRCC. Using this data, Pearson correlation identified migrasome-associated lncRNAs, and Cox regression analysis was utilized to build a prognostic model. Subsequently, the model’s utility was validated against clinical characteristics from multiple perspectives. Enrichment results, immune infiltration analysis, Tumor Mutational Burden (TMB), and Tumor Immune Dysfunction and Exclusion (TIDE) analysis delineated differences in the tumor immune microenvironment. Quantitative real-time polymerase chain reaction (qPCR) confirmed the expression of key lncRNAs in the model. Finally, a interference plasmid for UBE2Q1-AS1 was constructed and transfected into 786-O cells. The CCK-8 assay and Transwell assay were then used to verify its effects on cell proliferation and migration. A prognostic model incorporating 12 migrasome-associated lncRNAs with independent prognostic value was developed, demonstrating robust predictive power across various clinical features. Enrichment and immune infiltration analyses revealed significant disparities in immune responses between groups. TMB and TIDE analyses indicated that high TMB groups had lower survival rates compared to low TMB groups, and TIDE scores were greater for high-risk groups than for low-risk groups. Additionally, the quantities of expression for migrasome-associated lncRNAs were validated in human ccRCC cell line. Cell experiments revealed that interference of UBE2Q1-AS1 significantly inhibited the proliferation and migration of 786-O cells. The migrasome-associated lncRNA model accurately predicts ccRCC patient prognosis, offering new insights for immunotherapy and clinical applications.